Guide the development of technology-based solutions (TBS) with clinical utility for respiratory and allergic airway diseases

Define, refine and validate tools (e.g. databases, indicators) for real-world research on respiratory and allergic airways disease

Define, refine and validate clinical tools for the real-world management of respiratory and allergic airways disease

Provide methodological support for high quality real-world research

Understand the clinical and cost implications of comorbidities (and their treatments) in patients with respiratory and allergic airway diseases

Improve understanding of medication adherence behaviours (including inhaler device challenges) in respiratory and allergic airways disease, their implications on clinical and health economic outcomes and optimised management options

Understand the role of maintenance inhaled therapy particle size on outcomes in respiratory and allergic airways disease

PROPOSED STUDIES

Implications of ICS particle size on the management of routine care patients with a mixed asthma-COPD phenotype

ACTIVE STUDIES

A systematic review of the comparative effectiveness literature considering extra-fine particle ICS with licensed alternatives
The implications of particle size on ICS dose response in patients with asthma
Implications of ICS particle size on potential long-term asthma treatment-related side effects (e.g. metabolic and musculoskeletal comorbidities, pneumonia)

COMPLETED STUDIES

Comparative effectiveness of stepping-up asthma maintenance therapy as extrafine versus non-extrafine particle ICS
Comparative effectiveness of initiating asthma maintenance therapy as extrafine versus non-extrafine particle ICS
Comparative effectiveness of extrafine ICS + LABA versus non-extrafine ICS + LABA as step-up therapy for patients with uncontrolled asthma

Cost Effectiveness - COMPLETED STUDIES

Cost-effectiveness of initiating extrafine- versus non extrafine ICS for the management of asthma
Cost-effectiveness of asthma step-up therapy as an increased dose of small-particle inhaled corticosteroid or add-on long-acting beta2-agonist

Asthma - Smokers - COMPLETED STUDIES

Implications of ICS particle size for the management of asthma in patients with current / past smoking history

Asthma - Paediatrics - ACTIVE STUDIES

Comparative effectiveness of stepping up maintenance therapy as extra fine ICS versus fixed dose combination (non-extrafine) ICS/LABA therapy in routine care paediatric asthma management
Comparative effectiveness of extra-fine particle ICS compared with guideline recommended alternative treatment options for patients with pre-school asthma / wheeze

COMPLETED STUDIES

Comparative effectiveness of extrafine particle versus guideline recommended alternatives as first- and step-up maintenance therapy in children

COPD - COMPLETED STUDIES

Comparative effectiveness of extrafine versus non extrafine ICS for the management of routine care patients with COPD

Comorbidities - PROPOSED STUDIES

Implications of ICS particle size on the management of respiratory patients with comorbid GERD

ACTIVE STUDIES

Comparative effectiveness of spacers for the delivery of extrafine veruss non-extrafine particle ICS in asthma

Evaluate the comparative effectiveness of treatments (guideline-recommended / not recommended but frequently used) in respiratory and allergic airways disease, and associated characteristics of the patients, the disease, the ecology of care

PROPOSED STUDIES

Comparative effectiveness of triple therapy versus guideline recommended dual therapy (ICS/LABA and LAMA/LABA) alternatives in patients with COPD
Implications of steroid tailoring on treatment outcomes in patients with COPD managed in routine care

ACTIVE STUDIES

Comparative effectiveness of guideline recommended treatment options for patients with pre-school asthma / wheeze

COMPLETED STUDIES

Comparative effectiveness of Step three treatment options in children with asthma
Clinical predictors of prescribed step three treatment in paediatrics